Clinical trial
A Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B530, an Autologous Logic-gated Tmod™ Chimeric Antigen Receptor T Cell (CAR T), in Heterozygous HLA-A*02 Adult Subjects With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
NCT05736731 is registered in ClinicalTrials.gov with A2 Biotherapeutics Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B530, an Autologous Logic-gated Tmod™ Chimeric Antigen Receptor T Cell (CAR T), in Heterozygous HLA-A*02 Adult Subjects With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
- Lead sponsor
- A2 Biotherapeutics Inc.
- Phase
- Phase 1/2
- Overall status
- Active, not recruiting
- Start date
- April 28, 2023
- Completion date
- December 31, 2026
- Enrollment
- 160 (estimated)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.
cancer, colorectal adenocarcinoma, colorectal cancer, colorectal cancer metastatic, colorectal neoplasms, crc, non small cell lung cancer, non small cell lung cancer recurrent, non-small cell squamous lung cancer, nsclc, nsclc, recurrent, pancreas cancer, pancreatic cancer, pancreatic neoplasms, solid tumor, solid tumor, adult